Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.…
Helus Pharma (HLP) Stock Fair Value Rises After HLP003 Phase 3 Analyst Revisions
Helus Pharma (NASDAQ: HELP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 100 employees.
The shares were at 6.110 USD on 20 November 2026, down 5.4% over 52 weeks. Its 52-week range is 3.760 USD to 15.15 USD: the price is 59.7% below the high and 62.5% above the low.
Its market capitalisation is 487.68M USD.
Helus Pharma reports return on equity of -63.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 166.36M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 February 2027.